Review Article

The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?

Jeffrey M. Ryckman a,⇑, Bradley N. Reames c, Kelsey A. Klute d, William A. Hall e, Michael J. Baine b, May Abdel-Wahab f, Chi Lin b

a Department of Radiation Oncology, West Virginia University Cancer Institute, Parkersburg, WV, USA
b Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA
c Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA
d Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
e Department of Medical Oncology, University of Nebraska Medical Center, Omaha, NE, USA
f Division of Human Health, International Atomic Energy Agency, Vienna, Austria

A R T I C L E   I N F O

Article history:
Received 4 February 2021
Revised 6 April 2021
Accepted 7 April 2021

Keywords:
Pancreatic cancer
Stereotactic body radiotherapy
Total neoadjuvant therapy

A B S T R A C T

Stereotactic Radiotherapy (SRT) over 5-15 days can be interdigitated without delaying chemotherapy. Bridging chemotherapy may allow for extended intervals to surgery, potentially improving sterilization of surgical margins and overall survival. SRT for pancreatic adenocarcinoma should not be limited to the tumor, and should consider hypofractionated approaches to regional nodes.

© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

The prognosis of pancreatic cancer

Pancreatic cancer has a poor prognosis, with a five-year overall survival (OS) of 3–14% in the non-metastatic setting [1]. Surgery has always played a vital role in treatment, potentially curing patients eligible to undergo complete resection of localized pancreatic cancer [2]. Unfortunately, over half of patients present with metastases while only 10–20% have localized potentially resectable disease, leaving around 30% classified as borderline resectable (BR) or locally advanced pancreatic cancer (LAPC) [3,4]. Neoadjuvant therapy (NAT) has emerged as a standard approach for patients with BR and LAPC. Patients typically receive upfront combination chemotherapy for 2–4 months to treat micrometastatic disease, assess tumor biology, and increase the likelihood of margin-negative resection through margin sterilization and downstaging. Early systemic therapy is important, as approximately 30–50% of patients with LAPC will have evidence of metastatic disease within three months of diagnosis [4].
The high rate of distant metastasis associated with pancreatic cancer underscores the importance of systemic therapy. Two recent trials of adjuvant chemotherapy (ESPAC-4, PRODIGE 24) in highly selected patients eligible for upfront surgical resection reported unprecedented median survival ranging from 30 to 54 months [5,6]. However, these trials also suggested an incidence of microscopically positive surgical margins (i.e., R1 resections) for upfront surgery ranging from 40 to 60% [5,7]. Negative (i.e., R0) resection margins are most challenging to obtain posteriorly, and appear to be strongly associated with isolated surgical bed recurrence [8]. Local failure is a known contributor to demise, as demonstrated by a classic autopsy series reporting 30% of patients died with locally destructive pancreatic cancer [9]. Pain from a lack of local control is known to affect quality of life adversely [10]. Moreover, ESPAC-4 and PRODIGE 24 demonstrated anywhere from 30–40% of patients treated with upfront surgery will not receive all recommended adjuvant therapy due to surgical morbidity, poor performance, refusal, or early recurrence, thereby strengthening the rationale for a neoadjuvant approach [1].

Neoadjuvant chemotherapy (NAC) is associated with decreased rates of pancreatic fistulas and clinical sequelea, such as delayed gastric emptying and surgical site infections, which commonly contribute prolonged post-surgical recovery and a delay in adjuvant therapy [11]. NAC facilitates early treatment of micrometastatic disease and allows for the identification of occult metastatic disease, facilitating appropriate patient selection for surgery. A recent meta-analysis comprised of 38 studies with 3,484 resectable or BR pancreatic cancer patients suggested NAT, i.e., NAC with or without radiotherapy (RT), appears to improve OS by intention to treat, despite lower overall resection rates in the patients who received NAT [12]. NAT was also associated with lower rates of pathologically positive lymph nodes and more R0 resections than upfront surgery alone [12].

However, preoperative chemotherapy alone may not be enough for some cases of BR and LAPC. A recent prospective study of 680 BR and LAPC patients suggested the receipt of complementary neoadjuvant radiation, in addition to chemotherapy, correlated with improved survival [13]. A large retrospective report of total neoadjuvant therapy (TNT) for LAPC demonstrated CA 19–9 response, >6 preoperative chemotherapy cycles, and major pathologic response to be independently associated with improved regression free survival and OS [14]. Of these three factors, major pathologic response was associated with the largest incremental benefit in OS [14].

Improving chances of successful surgery

Many complexities make the treatment of pancreatic cancer a challenge, including aggressive biology, early metastases, difficult anatomic location, intense non-surgical therapy, and cancer cachexia, making all of the above worse. Even in a trial setting, 30–40% of patients treated with upfront surgery will not receive all recommended adjuvant therapy due to surgical morbidity, poor performance, refusal, or early recurrence, thereby strengthening the rationale for a neoadjuvant approach [1].

Neoadjuvant chemotherapy (NAC) is associated with decreased rates of pancreatic fistulas and clinical sequelea, such as delayed gastric emptying and surgical site infections, which commonly contribute prolonged post-surgical recovery and a delay in adjuvant therapy [11]. NAC facilitates early treatment of micrometastatic disease and allows for the identification of occult metastatic disease, facilitating appropriate patient selection for surgery. A recent meta-analysis comprised of 38 studies with 3,484 resectable or BR pancreatic cancer patients suggested NAT, i.e., NAC with or without radiotherapy (RT), appears to improve OS by intention to treat, despite lower overall resection rates in the patients who received NAT [12]. NAT was also associated with lower rates of pathologically positive lymph nodes and more R0 resections than upfront surgery alone [12].

However, preoperative chemotherapy alone may not be enough for some cases of BR and LAPC. A recent prospective study of 680 BR and LAPC patients suggested the receipt of complementary neoadjuvant radiation, in addition to chemotherapy, correlated with improved survival [13]. A large retrospective report of total neoadjuvant therapy (TNT) for LAPC demonstrated CA 19–9 response, >6 preoperative chemotherapy cycles, and major pathologic response to be independently associated with improved regression free survival and OS [14]. Of these three factors, major pathologic response was associated with the largest incremental benefit in OS [14].

Improving radiation techniques

Radiation therapy (RT) has failed to prove a consistent benefit in OS when utilizing traditional, protracted techniques. However, there is also an absence of large, well conducted trials to have tested this when giving protracted courses of CCRT in the neoadjuvant setting. Conventional fractionation schemes around six weeks in duration typically use concurrent fluoropyrimidines or gemcitabine at radiosensitizing doses, which are likely inadequate for the prevention of metastases. The pancreas is difficult to treat with RT due to the proximity of radiosensitive healthy tissues such as the stomach and duodenum. However, modern techniques have demonstrated hypofractionated pancreatic stereotactic RT (SRT) alone or concurrently with cetapitabine [NCT03073785] [15] over 5–15 days is safe and effective, and less than 10% of patients will experience severe adverse effects [16]. Prior arguments against the use of RT in a protracted manner due to the resulting delay in necessary systemic treatment are no longer valid with SRT. Perhaps most importantly, SRT may be offered before surgery without taking the option of systemic therapy or surgical intervention off the table.

Dose painting techniques are incredibly technical and vary by institution. Many centers advocate for dose-painting to vascular areas of concern [17,18]. When utilizing a five-fraction regimen, a minimum of 33 [19–21] or 35[22] to 40 [23] Gy to gross disease is recommended. Further increases in total dose and dose per fraction are possible, with two studies demonstrating dose escalation up to 60 Gy in 5 fractions is dosimetrically feasible with adequate Planning Target Volume coverage and respect of Organs at Risk dose constraints [24,25]. Patients or tumors which may not be candidates for surgery may be well served by more prolonged hypofractionated regimens (e.g., 67.5/15 or 75/25; BED 10 Gy), especially for tumors less than 1 cm away from luminal structures [26]. Biologically equivalent dose (α/β = 10) ranging from a minimum of 48/27 [27] Gy to 60 [22] to 72 [24,28] Gy have been associated with improved OS, in keeping with a minimum of 30–40/5, 35–48/10 or 38–53/15. Fiducials or real time Magnetic Resonance Imaging tracking serve to localize the tumor, and accuracy of treatments is within 2–3 mm. Near-misses are of concern with such steep gradients. Modern imaging appears to underestimate the true pathologic size of the tumor by at least 4 mm, which presents additional challenges in highly conformal irradiation of pancreatic tumors, warranting further investigation of optimal tumor volumes and dosing [29–31]. Areas of clinical microscopic risk, including nodal regions, around the celiac trunk and superior mesenteric artery should be included based on patterns of failure [22,32]. ESTRO guidelines support the consideration of elective nodal irradiation (ENI) for resectable tumors, as the importance of local control decreases in the context of surgery [33]. Further, single institution data has suggested rare out of field failures with five fraction regimens mandating ENI [34].

An ongoing trial of NAC with or without consolidative SRT in BR pancreatic cancer recently closed at interim analysis due futility [NCT02839343] [35]. There are several concerns with the introduction of SRT to the tumor only, in the pre-operative setting in this trial, clearly the early futility termination of this trial raises con-
cerns regarding the use of pre-operative SBRT outside of high volume centers for resecting BRPC [36]. Current paradigm for TNT in pancreatic cancer is to deliver induction chemotherapy and perform surgery within 4–8 weeks after completion of neoadjuvant RT (if performed). It is not surprising to see pathologic complete response (pCR) rates after TNT of around 10% to be among the most commonly reported, which is low even for adenocarcinomas [14,37-39].

Achieving maximum tumor regression prior to surgery

Surgeons often prefer to operate within 6–8 weeks after RT due to concerns for radiation fibrosis, which could lead to increased technical difficulty and complications including intraoperative and post-operative hemorrhage [40]. Recent studies have suggested that neoadjuvant therapy is not associated with increased morbidity or mortality [11,41].

The sequencing of preoperative chemotherapy and radiation in pancreatic cancer has not been evaluated in a randomized setting. We are aware of two trials which demonstrate the feasibility and safety of RT followed by consolidative chemotherapy for BR pancreatic cancer with promising rates of R0 resections [42,43]. Notably, both trials utilized prolonged fractionation concurrent chemoRT (CCRT) followed by consolidative gemcitabine for two [43] or three months [42], the latter performing surgery five months after RT with reasonable rates of perioperative complications.

The evolving paradigm in sequencing of neoadjuvant therapy in rectal cancer provides some consideration for shifting the timing of radiation in pancreatic cancer; although differences in these two malignancies is recognized. Considerable data has investigated the impact of extending the interval between radiation and surgery with longer durations of consolidative chemotherapy. Such an approach may allow for maximal tumor regression after radiotherapy and surgery to be performed months later. The TIMING trial for rectal adenocarcinoma is a landmark phase II study that specifically investigated the impact on pCR by progressively extending the interval from CCRT to surgery with oxaliplatin-based chemotherapy. In this setting, pCR more than doubled from 18% to 38% when adding three months of oxaliplatin-based chemotherapy after CCRT as compared to the control arm, which received no preoperative oxaliplatin-based chemotherapy after radiotherapy. Pelvis fibrosis was increased, but consistently stable between experimental groups despite increasingly prolonged intervals to surgery. Importantly, there were no differences in technical difficulty of the operation or perioperative complications even though patients underwent surgery six weeks versus five months after radiotherapy in the control and experimental arms, respectively [44]. This concept was also investigated in the context of SRT with reasonable rates of perioperative complications [45,46]. Further, preliminary data from OPRA has suggested upfront CCRT followed

![Fig. 1. Example of a Phase I Trial Schema Investigating Earlier Interdigitation of Preoperative Stereotactic Radiotherapy (SRT)](image)
by consolidation chemotherapy results in maximum tumor regression as compared to induction chemotherapy followed by CCRT [47]. This paradigm of earlier interdigitiation of radiotherapy warrants investigation in pancreatic cancer to understand its impact on improving survival. Only large, well designed, prospective trials, can address and answer these important questions in pancreatic cancer.

**Considerations for a novel multidisciplinary treatment paradigm for pancreatic cancer**

An upfront or earlier interdigitiation of preoperative radiotherapy is a strategy that could be considered for pancreatic adenocarcinoma, so long as there is no resulting delay in systemic therapy or increase in perioperative complications. Fig. 1 presents a potential trial schema to test this hypothesis. Patients with BR and LAPC without evidence of liver metastases on MRI would be eligible. Routine staging laparoscopy before clinical trial registration would be utilized to improve patient selection, as best available data suggest that around 25% of patients will have radiographically occult peritoneal disease [48–50]. Randomization would begin after receipt of the induction portion of chemotherapy to avoid loss of power which may occur for patients who develop progressive disease while on chemotherapy. CA 19–9 would be assessed at study entry, prior to radiotherapy, prior to consideration of surgery, and post-operatively (if completed). Factors influencing the decision to resect are multifactorial, including no evidence of progression or development of new metastatic disease, evidence of biochemical response or stability as determined by serum tumor markers, performance status of 0 or 1, and absence of life-limiting comorbidities. As radiographic response does not appear to predict surgical resectability [14,51–54], the decision to proceed with exploration and possible resection would be determined by the operating surgeon after multidisciplinary review and discussion. A central review board may also be considered to assist with determination of surgical eligibility as is done in the ongoing LAPIS trial [NCT03941903].

If Study Group (SG) 1 and SG2 result in reasonable rates of perioperative complications and favorable R0 resection rates, radiotherapy may be delivered perhaps as soon as after the first or second cycle of chemoradiotherapy (SG3, Fig. 1). Once the safest, longest interval between SRT and surgery has been determined, a Phase II trial could be conducted to investigate the efficacy of the proposed regimen. Co-primary endpoints could be resection rate and major pathologic response while secondary endpoints might investigate peri-operative complications, local control, overall survival, and quality of life, for example.

Elective nodal volumes (i.e., celiac trunk and superior mesenteric artery +/- hepatic artery, superior mesenteric vein, and portal vein) utilizing simultaneous integrated boost would be mandated to minimize marginal miss [15,17,34,55]. Five to fifteen fractions would be allowable on our sample schema while controlling for time to surgery from completion of radiotherapy, favoring the latter in the context of gross primary or nodal disease nearby to organs at risk [17].

Importantly, pancreatic cancer guidelines now support the upfront use of concurrent CRT or SRT as a part of neoadjuvant therapy for some non-metastatic patients based on patient and physician preference [4,56]. The hypothesis of adjusting the timing of radiotherapy is within an acceptable standard of care and an ongoing study is investigating consolidative chemotherapy after SRT [NCT03460925]. The sample study design would supplement this hypothesis by investigating the timing to surgery with the goal of extending the duration of consolidative chemotherapy.

Preoperative radiotherapy is emerging as an approach to pancreatic cancer with several potential advantages. Earlier integration of radiotherapy followed by consolidative systemic therapy may be a promising management strategy. If shown to be safe and feasible, this novel multidisciplinary treatment paradigm has the potential to improve oncologic outcomes, including R0 resection, major pathologic response, and overall survival.

**Declaration of Competing Interest**

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Hall's department receives research and travel support from Elekta AB, Stockholm, Sweden. All other authors declare no conflicts of interest.

**References**

[1] D’Angelo F, Antolino L, Farcomeni A, Sirimarro D, Nava AK, De Siena M, et al. Neoadjuvant treatment in pancreatic cancer: evidence-based medicine? A systematic review and meta-analysis. Med Oncol 2017;34:85.
[2] Khosravani AA, McKernin SE, Berlin J, Hong TS, Maitra A, Moravec C, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol 2019;37:2082–8.
[3] Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer 2018:18:688.
[4] Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, et al. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg 2019.
[5] Mcintyre CA, Zambrinis CP, Pulvirenti A, Chou JF, Gonen M, Balchandran VR, et al. Detailed analysis of margin positivity and the site of local recurrence after pancreaticoduodenectomy. Ann Surg Oncol 2020;1–11.
[6] Jacobus-Donahue CA, Fu B, Yachida S, Lue M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009;27:1806.
[7] Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004:291:1092–9.
[8] Krell RW, McNeil LR, Yanala UR, Are C, Reames BM. Neoadjuvant therapy for pancreatic ductal adenocarcinoma: propensity-matched analysis of postoperative complications using ACS-NSQIP. Ann Surg Onc 2021.
[9] Versteijne E, Vogel JA, Besselsink M, Busch O, Wilmink J, Daams J, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg 2018;105:946–58.
[10] Maggio I, Malleo G, Marchegiani G, Viviani E, Nessi C, Cipriani D, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg 2019;154:932–42.
[11] Truty MJ, Kendrick RL, Halloran CM, Palmer DH, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/local advanced pancreatic cancer. Ann Surg 2019.
[12] Witt JS, Kuczynska-Haas A, Lubner M, Reeder SB, Cho SY, Minter R, et al. A phase 1 dose Escalation study of neoadjuvant SBRT plus elective nodal radiation with concurrent cetuximab for resectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2020.
[13] Petrelli F, Comito T, Ghidini A, Torri V, Scorsetti M, Barni S.BJorORBP. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. Int J Radiat Oncol Biol Phys. 2017;97:113–22.
[14] Koay EJ, Hanania AN, Hall WA, Taniguchi CM, Rebueno N, Myrehaug S, et al. Dose-escalated radiation therapy for pancreatic cancer: a simultaneous integrated boost approach. Pract Radiat Oncol. 2020.
[15] Shain H, Hawke N, Cassidy RJ, Chen Z, Zhang B, Crutcher E, et al. A Phase 1 study of stereotactic body radiation therapy dose escalation for borderline resectable pancreatic cancer after modified FOLFIRINOX (NCT01464458). Int J Radiat Oncol Biol Phys 2016:90:296–303.

127
The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience. Ann Surg Oncol 2015;22:2352–8.

Pollom EL, Algagapan M, Von Eyben K, Kunz PJ, Fisher GA, Ford JA, et al. Single-via multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Int J Radiat Oncol Biol Phys 2014;90:918–25.

Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 2015;121:1128–37.

Zhu X, Ju X, Cao Y, Shen Y, Cao F, Qin S, et al. Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: implications of target volume design. Int J Radiat Oncol Biol Phys 2019;104:101–10.

Qar A, Lee M, Le H, Hruby G, Dalsfen R, Pryor D, et al. Australasian gastrointestinal trials group (AGITG) and trans-s tasman radiation oncology group (TROG) guidelines for pancreatic stereotactic body radiation therapy (SBRT). Pract Radiat Oncol 2019.

Colbert LE, Reuben N, Moningi S, Beddar S, Sawalshki GO, Herman JM, et al. Dose escalation for locally advanced pancreatic cancer: how high can we go?. Adv Radiat Oncol 2018;3:693–700.

Mazzarotto R, Simon N, Guariglia S, Rossi G, Micera R, De Robertis R, et al. Dosimetric feasibility study of dose escalated stereotactic body radiation therapy (SBRT) in locally advanced pancreatic cancer (LAPC): it is time to raise the bar. Front Oncol 2020;10.

Reynold M, O'Reilly EM, Varbge AM, Fiasconaro M, Zinovov M, Romesser PB, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer. JAMA Oncol 2021.

Arcelli A, Guido A, Buisine M, Simon N, Mazzarotto R, Macchia G, et al. Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: a multicentric analysis (PAULA-1). Anticancer Res 2020;40:465–72.

Lin C, Verma V, Ly QP, Lazenby A, Saxon A, Schwarz JK, et al. Phase I trial of concurrent stereotactic body radiotherapy and neflatinib for locally advanced borderline or unresectable pancreatic adenocarcinoma. Radiother Oncol 2019;132:55–62.

Arvold ND, Niemierko A, Mamon HJ, Fernandez-del Castillo C, Hong TS. Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys 2011;80:1383–90.

Qu H, Wild AT, Wang H, Fishman EK, Hruban RH, Laheru DA, et al. Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning. Radiother Oncol 2012;104:167–72.

Hall WA, Mikell JL, Mittal P, Colbert L, Prabhu RS, Kooby DA, et al. Tumor size on abdominal MRI versus pathologic specimen in resected pancreatic adenocarcinoma: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys 2013;86:102–7.

Dhillon AS, Hacker-Prietz A, Wild AT, Raman SP, Wood LD, Huang P, et al. Resection of borderline resectable pancreatic cancer: a prospective, randomized, open-label, phase II trial. J Clin Oncol 2016;34:3773–80.

Verma V, Li J, Lin C. Neoadjuvant therapy for pancreatic cancer: systematic review of postoperative morbidity, mortality, and complications. Ann J Clin Oncol 2016;39:302–13.

Hayashi T, Nakamura T, Kimura Y, Yoshida M, Someya M, Kawakami H, et al. Phase IIb study of neoadjuvant treatment of sequential S-1-based concurrent chemoradiation therapy followed by systemic chemotherapy with gemcitabine for borderline resectable pancreatic adenocarcinoma (HOPS-BR 01). Int J Radiat Oncol Biol Phys 2019;105:506–17.

Takahashi H, Ohgishi H, Gotoh K, Marubashi S, Yamada T, Murata M, et al. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg 2013;258:1040–50.

Garcia-Agulgar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, et al. Effect of adding mFOLFIRINOX after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 2015;16:957–66.

Buiko K, Wyrwicz L, Rutkowski A, Mala inowska M, Pietrzk L, Kryńska J, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5-Fl ozol and consolidation chemotherapy for ct4 or fixed ct3 rectal cancer: results of a randomized phase III study. Ann Oncol 2016;27:834–42.

Chapman W, Kim H, Bauer P, Makhdoum B, Trikalinos N, Pedersen K, et al. Total neoadjuvant therapy with short course radiation compared to concurrent chemoradiation in rectal cancer. J Clin Oncol 2019;37:486.

Garcia-Agula J, Patil S, Kim JK, Yuval JB, Thompson V, Herfey H, et al. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. J Clin Oncol 2020;38:4008.

Tienhoven GV, Versteijne E, Sutker M, Groothuis KBC, Busch OR, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREEOPANC-1): a randomized, controlled, multicenter phase III trial. J Clin Oncol 2018;36, LBA4002-LBA.

Jang J-Y, Han Y, Lee H, Kim S-W, Kwon W, Lee K-H, et al. Oncologic benefits of neoadjuvant chemotherapy with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg 2018;268:215–22.

Peters GW, Hallmeier CL, Jethwa KR. Time to Reconsider Staging Laparoscopy in Pancreatic Cancer? Journal of Clinical Oncology:JCO.20.00996.

Cassinotto C, Cortade J, Belleannée G, Lapuyade B, Terrebonne E, Vendrely V, et al. An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol 2011;80:1383–90.

Zhu X, Ju X, Cao Y, Shen Y, Cao F, Qin S, et al. Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: implications of target volume design. Int J Radiat Oncol Biol Phys 2019;104:101–10.

Hall WA, Mikell JL, Mittal P, Colbert L, Prabhu RS, Kooby DA, et al. Tumor size on abdominal MRI versus pathologic specimen in resected pancreatic adenocarcinoma: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys 2013;86:102–7.

Dhillon AS, Hacker-Prietz A, Wild AT, Raman SP, Wood LD, Huang P, et al. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships. J Radiat Oncol 2013;2:413–25.

Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EJ, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015;261:12–7.

Katz MH, Fleming JB, Bhosale P, Varadchachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 2012;118:7494–56.

Nakamura A, Prichard HA, Wo YJ, Wolfgang JA, Hong TS, Elective nodal irradiation with simultaneous integrated boost stereotactic body radiotherapy for pancreatic cancer: Analyses of planning feasibility and geometrically driven DVH prediction model. J Appl Clin Med Phys 2015;20:71–83.

Paleta M, Godfrey D, Goodman KA, Hoffs S, Dausson LA, Dessert D, et al. Radiation therapy for pancreatic cancer: Executive summary of an ASTRO clinical practice guideline. Practical radiat Oncol 2019;9:322–32.